MUSCAT: Pharmaceutical giant AstraZeneca has “voluntarily paused” a clinical trial of its coronavirus vaccine after a volunteer developed an unexplained illness.
The company, which is developing the drug alongside the University of Oxford in the UK, is a frontrunner in the global race for a COVID-19 vaccine.
“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” a spokesperson said.
Read More
- HH Sayyid Shihab presides over recital of Prophet’s life story at Al Alam Palace
- Oman’s CPA shuts travel agency in Rustaq over failure to deliver promised services
- Oman expands organic farm Yuzu to boost food security and local production
- Oman to host ICESCO delegation in Dhofar to strengthen cultural diplomacy and cooperation
- Dhofar Municipality launches wage support scheme for seasonal Omani workers
“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline,” the spokesperson added.
